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Background
Cardiovascular disease is the leading cause of mortality
in type 1 diabetics (T1D). T1D patients have increased
coronary artery calcification (CAC) compared to non-
diabetics. We hypothesize that myocardial blood flow
(MBF) reserve can be measured in long-standing T1D
patients using regadenoson stress cardiac magnetic reso-
nance (CMR) perfusion imaging and is a marker of
extensive atherosclerotic disease associated with CAC.
Methods
RABIT1D is a sub-study of the Coronary Artery Calcifi-
cation in Type 1 Diabetics (CACTI) study that established
a cohort of 656 T1D patients and 764 non-diabetic
controls that was followed for progression of CAC over 6
years with electron beam tomography. Non-diabetic
controls with CAC > 100 (n = 4), T1D patients with CAC
< 100 (n = 5, DM1), and T1D patients with CAC > 100 (n
= 16, DM2) were recruited to complete sequential regade-
noson stress nuclear imaging (MPI) and CMR perfusion
imaging. CAC scores for the three groups are located in
Figure 1. Patients with abnormal MPI were referred for
invasive coronary flow reserve measurements in a cardiac
catheterization lab. Twenty-three cardiac MRI studies
were performed of which 20 were analyzable (n = 4 in
control, n = 4 in DM1, n = 12 in DM2). Three studies
were not analyzable due to poor image quality from
motion, system error, and a patient dropping out of the
study. CMR perfusion imaging was performed at rest fol-
lowed by imaging during maximal vasodilation after 400
mcg injection of regadenoson. CMR images were acquired
with a 4 channel phased array surface coil. Three simulta-
neous short-axis slices (basal, mid, and apical) were
acquired during an initial bolus injection of gadolinium
(ProHance, 0.05 mmol/kg at a rate of 5 mL/sec). SSFP
imaging sequence was used with TR, TE, flip angle of 185
ms, 1.2 ms, 50 degrees, respectively, and inserted into a
330 × 380 matrix. Images were acquired using a field of
view ranging from 280 to 400 mm. MBF reserve measure-
ments were obtained from 6 regions within the mid-
ventricular short axis slice using the Fermi deconvolution
method.
Results
MBF reserve mean value was 2.19 ± 0.3 for the moderate
risk non-diabetic controls while MBF for the low and
high risk T1D groups were 1.81 ± 0.6 and 1.95 ± 0.7,
respectively. There was a significant difference between
the controls and DM1 group (p = 0.001, *) and DM2
group (p = 0.007, **) demonstrated in Figure 2. No
difference was noted between DM1 and DM2 groups
(p = 0.067).1Cardiology, University of Colorado, Denver, Colorado, USA
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Figure 1 Coronary artery calcium score by study group.
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Conclusions
MBF reserve was successfully measured in regadenoson
CMR perfusion imaging studies. Regadenoson stress
imaging was safe in the T1D patient groups. In this pre-
liminary study, the impaired vasodilator reserve in T1D
patients may indicate more extensive atherosclerotic dis-
ease than in moderate-risk controls with similar or
higher CAC scores.
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Figure 2 Myocardial blood flow reserve by study group.
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